Milly E. de Jonge

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

Milly E. de Jonge, Alwin D. R. Huitema, Jos H. Beijnen et al. · British Journal of Cancer · 2006 · 78 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

Milly E. de Jonge, Alwin D. R. Huitema, M. Holtkamp et al. · Cancer Chemotherapy and Pharmacology · 2005 · 64 citations

Medicine, Pharmacology, Pharmacotherapy +7

Simultaneous quantification of cyclophosphamide, 4‐hydroxycyclophosphamide, <i>N</i>,<i>N</i>^′,<i>N</i>^″‐triethylenethiophosphoramide (thiotepa) and <i>N</i>,<i>N</i>^′,<i>N</i>^″‐triethylenephosphoramide (tepa) in human plasma by high‐performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Milly E. de Jonge, Selma M. van Dam, M. J. X. Hillebrand et al. · Journal of Mass Spectrometry · 2004 · 61 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function

Corine Ekhart, Milly E. de Jonge, Alwin D. R. Huitema et al. · Clinical Cancer Research · 2006 · 57 citations

Pharmacy, Oncology, Pharmacokinetics +17

Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer

Milly E. de Jonge, H.J.G.D. van den Bongard, Alwin D. R. Huitema et al. · Clinical Cancer Research · 2004 · 51 citations · Full text

Medicine, Oncology, Pharmacology +15